Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Kazuhiro Koikawa, Shin Kibe, Futoshi Suizu, et al.
Cell (2021) Vol. 184, Iss. 18, pp. 4753-4771.e27
Open Access | Times Cited: 159

Showing 1-25 of 159 citing articles:

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Hirohito Yamaguchi, Jung-Mao Hsu, Wenhao Yang, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 5, pp. 287-305
Closed Access | Times Cited: 331
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 299
Translational advances in pancreatic ductal adenocarcinoma therapy
Abdel Hosein, Stephanie K. Dougan, Andrew J. Aguirre, et al.
Nature Cancer (2022) Vol. 3, Iss. 3, pp. 272-286
Open Access | Times Cited: 177
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials
Hao Zhang, Xinghai Yue, Zhe Chen, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 146
Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade
Liam Jenkins, Ute Jungwirth, Alexandra Avgustinova, et al.
Cancer Research (2022) Vol. 82, Iss. 16, pp. 2904-2917
Open Access | Times Cited: 141
IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment
Bo Hu, Mincheng Yu, Xiaolu Ma, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1718-1741
Open Access | Times Cited: 129
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu‐Tian Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 125
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Liping Pei, Yang Liu, Lin Liu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 115
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
Chiara Falcomatà, Stefanie Bärthel, Günter Schneider, et al.
Cancer Discovery (2023) Vol. 13, Iss. 2, pp. 278-297
Open Access | Times Cited: 102
The hallmarks of cancer immune evasion
Claudia Galassi, Timothy A. Chan, Ilio Vitale, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1825-1863
Closed Access | Times Cited: 70
Cancer Spheroids and Organoids as Novel Tools for Research and Therapy: State of the Art and Challenges to Guide Precision Medicine
Sanae El Harane, Bochra Zidi, Nadia El Harane, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1001-1001
Open Access | Times Cited: 66
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Shuangneng Yin, Zhaojun Chen, Dugang Chen, et al.
Theranostics (2023) Vol. 13, Iss. 5, pp. 1520-1544
Open Access | Times Cited: 62
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria
Xiaoqing Xie, Yi Yang, Qiang Wang, et al.
Cell Research (2023) Vol. 33, Iss. 3, pp. 215-228
Open Access | Times Cited: 59
The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells
Qingyu Lin, Xingwen Wang, Ying Hu
Cancer Letters (2023) Vol. 569, pp. 216318-216318
Open Access | Times Cited: 53
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
Tianxing Zhou, Yongjie Xie, Xupeng Hou, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 51
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 36
Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Wenyu Luo, Ti Wen, Xiujuan Qu
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 24
Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance
Xiaozhen Zhang, Mengyi Lao, Hanshen Yang, et al.
Autophagy (2024) Vol. 20, Iss. 6, pp. 1314-1334
Open Access | Times Cited: 21
Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment
Yu-Heng Zhu, Jia-Hao Zheng, Qin-Yuan Jia, et al.
Cellular Oncology (2022) Vol. 46, Iss. 1, pp. 17-48
Closed Access | Times Cited: 59
Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment
Steve Robatel, Mirjam Schenk
Cancers (2022) Vol. 14, Iss. 4, pp. 985-985
Open Access | Times Cited: 43
Exploration of the Use of Natural Compounds in Combination with Chemotherapy Drugs for Tumor Treatment
Jian Wu, Yunheng Li, Qiaojun He, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1022-1022
Open Access | Times Cited: 36
Photo‐Triggered Cascade Therapy: A NIR‐II AIE Luminogen Collaborating with Nitric Oxide Facilitates Efficient Collagen Depletion for Boosting Pancreatic Cancer Phototheranostics
Dan Li, Xiaohong Chen, Wenbin Dai, et al.
Advanced Materials (2023) Vol. 36, Iss. 13
Closed Access | Times Cited: 30
A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy
Zhuolong Zhou, Kevin Van der Jeught, Yujing Li, et al.
Advanced Science (2023) Vol. 10, Iss. 23
Open Access | Times Cited: 26
Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer
Shuying He, Wen D. Song, Shudan Cui, et al.
Cellular Oncology (2023) Vol. 46, Iss. 6, pp. 1731-1746
Open Access | Times Cited: 25
AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis
Zicheng Sun, Qiwei Jiang, Bing Gao, et al.
Cancer Research (2023) Vol. 83, Iss. 8, pp. 1264-1279
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top